The financials
Maravai LifeSciences Holdings, Inc. by the numbers
Maravai LifeSciences Holdings, Inc. (MRVI) reported revenue of $66M in Q1 2026 (quarter ended March 31, 2026), up 41% from the same quarter a year earlier. That came with a gross margin of 51% and net loss of $3.7M. For the full year FY2025, revenue was $186M (−28% year on year) and net income −$131M. Its largest segment in 2026-Q2 was Tri Link at $25M, 79% of the disclosed total, just ahead of Cygnus at 21%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $66M | $47M | +41% |
| Gross profit | $34M | $7.7M | +336% |
| Operating income | −$2.2M | −$49M | n/a |
| Net income | −$3.7M | −$30M | n/a |
| Diluted EPS | −$0.02 | −$0.21 | n/a |
| Operating | Revenue | Share |
|---|---|---|
| Tri Link | $25M | 79% |
| Cygnus | $6.6M | 21% |
Business Segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Q2 2026Total $31.3M (-69%)
Tri Link grew +3.2% year on yearCygnus -1.9% year on year
Segment Latestquarter on quarteryear on year
- Tri Link$24.6M$24.6MQoQ -48%year on year +3.2%-48%+3.2%
- Cygnus$6.6M$6.6MQoQ -64%year on year -1.9%-64%-1.9%
- Biologics Safety Testing--QoQ -year on year ---
- Nucleic Acid Production--QoQ -year on year ---